Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple blood draw could spot tumor relapse before scans do

NCT ID NCT03012789

Diagnosis Sponsor: Wren Laboratories LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This study tests whether measuring gene transcripts in the blood can help diagnose neuroendocrine tumors and assess how completely surgery removed them. Researchers will track blood levels after surgery and compare them with imaging to see if a rise in these markers signals tumor recurrence. The trial enrolls 30 people with gastroenteropancreatic neuroendocrine tumors who are undergoing surgical resection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Measurement of gene transcripts in blood (NETest)
What this could lead to
If successful, this blood test could help doctors detect tumor recurrence earlier and more accurately than imaging alone, potentially improving follow-up care.
What could go wrong
This is a small, early-stage study. The blood test may not reliably predict recurrence in all patients, and results need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

May 2017

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pathologically confirmed, well differentiated (G1, G2 or G3), local and advanced (metastatic), neuroendocrine tumor of gastro-enteropancreatic origin. * Treatment-naïve as well as patients who have received previous therapies. * Patients currently on LAR with clinically stable disease. * CT or MRI documentation of disease. * WHO performance status ≤2. Exclusion Criteria: * Known history of HIV seropositivity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroenteropancreatic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine tumor, grade 1/2 neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastroenteropancreatic Neuroendocrine tumor

Contacts and locations

Locations

  • San Raffaele Hospital IRCCS

    Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.